IASIS PHARMA is pleased to announce the release of the new product Rami – Amlo plus® Rami – Amlo plus® is an original (prototype) fixed dose combination of Ramipril – Amlodipine -Hydrochlorothiazide Rami – Amlo plus® is indicated for the treatment of hypertension. Available in packs of 30 capsules, in a wide dosage range: Rami [...]
Grand Hyatt Hotel, Athens, 2 - 5/09/2021 IASIS PHARMA participated with physical presence in the 4th hybrid Panhellenic Congress under the title: “Dermatological diseases 2021: Past, present and future” which was held on September 2-5 at Grand Hyatt Hotel Athens. At IASIS PHARMA exhibition stand, two of its major Dermatological products were presented: Modiwart® / [...]
RAMANDA PLAZA THRAKI, Alexandroupoli, 2-5/09/2021 IASIS PHARMA with a high sense of responsibility and in response to the COVID-19 crisis peculiarities, successfully participated with physical presence in the 33rd Panhellenic Congress of Greek Association of General Practice, thus expressing its practical interest and support to the medical community. IASIS PHARMA has a wide portfolio of [...]
IASIS PHARMA expands its activities focusing on Greek nature, collaborating in the establishment of Natural Products Competence Center (NPCC). NPCC is a Collaborative Innovation Formation, with the participation of 15 partners from the academic and business sectors. The project is coordinated by the Laboratory for the Utilization of Bioactive Natural Products (Department of Pharmacy, National [...]
ATHENS CONCERT HALL, 11 - 12/06/2021 Despite COVID-19 pandemic predicaments, IASIS PHARMA successfully participated in the Annual Spring Day Hybrid (both with physical and in webinar form) Conference, held by the Hellenic Society of Dermatology and Venereology, which took place on June 11 – 12 at Athens Concert Hall - International Conference Centre. IASIS PHARMA participated actively in the event, [...]
Construction activities at the Chios Mastic Research and Development Center continue at an intensive pace, most recent being the completion of the air conditioning & ventilation systems. Since the project started, the basic intention of the facilities’ design was its typological differentiation from a "typical" industrial facility, but at the same time meeting pharmaceutical industry [...]
Hellenic Gastroenterological Society Amphitheater, Athens, 16-18/04/2021 IASIS PHARMA, with a high sense of responsibility and adapted to the peculiarities of the COVID-19 period, successfully participated in the 26th Greek Webinar for Helicobacter pylori & Other Digestive Infections. The conference was organized by the Hellenic Gastroenterological Society and the Hellenic Society for Infections and it was [...]
IASIS PHARMA has successfully launched COVED® to the Greek market. COVED® (Bisphosphonates, combinations) is a fixed dose combination of two active ingredients: Alendronic acid (as alendronate sodium trihydrate) (70mg) & Cholecalciferol (Vitamin D3) (5.600 I.U). COVED® 70 mg / 5,600 IU is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D [...]
IASIS PHARMA is pleased to announce the launch of the new 60 f.c. tabs packaging for GLUCOPLUS® 1.000mg (Metformin hydrochloride). Both GLUCOFREE® & GLUCOPLUS® (active ingredient: metformin hydrochloride) belong to the broader category of Oral Hypoglycemic Agents (OHAs) for the treatment of Type 2 Diabetes Mellitus (T2D) as first-line therapy. GLUCOFREE® is available in 850mg metformin hydrochloride, [...]
Winter vacation period has just ended, also affected by covid-19 pandemic. Nevertheless, IASIS PHARMA stayed focused on its corporate responsibility, in order all employees return to their jobs safely. More specifically, before their return, all IASIS PHARMA employees were re-tested for covid-19. The tests were carried out by a well-established private clinic at IASIS PHARMA [...]
